|
Recombinant humanised monoclonal IgG2 lambda antibody against human sclerostin |
|---|---|
| Trade Name | |
| Orphan Indication | Osteogenesis imperfecta |
| EU Market Approval | EU |
| EU Designation Date | 2016-06-27 00:00:00 |
| Sponsor | Mereo Biopharma 3 Limited |
Related Access Program
Agios Pharmaceuticals, Inc. – Acute Myeloid Leukemia
Novartis Pharmaceuticals – FLT3-mutated Acute Myeloid Leukemia
AbbVie – Acute Myeloid Leukemia (AML)
University of California, San Francisco – Acute Myeloid Leukemia
Emory University – Acute Myeloid Leukemia
British Columbia Cancer Agency – Thyroid Cancer, Medullary
Novartis Pharmaceuticals – Acute Myeloid Leukemia (AML) With
Beijing Cancer Hospital – Thyroid Nodules
Alnylam Pharmaceuticals – Amyloidosis, Hereditary
Alnylam Pharmaceuticals – TTR-mediated Amyloidosis
Astellas Pharma Global Development, Inc. – Acute Myeloid Leukemia (AML)
